

1 **Longitudinal experiences and impact of the COVID-19 pandemic among people with past or**  
2 **current eating disorders in Sweden**

3

4 Andreas Birgegård<sup>1\*</sup>, Afrouz Abbaspour<sup>1</sup>, Stina Borg<sup>1</sup>, David Clinton<sup>1</sup>, Emma Forsén  
5 Mantilla<sup>1</sup>, Jet D. Termorshuizen<sup>1,2</sup>, and Cynthia M. Bulik<sup>1,3,4</sup>

6

7 <sup>1</sup> Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm,  
8 Sweden

9 <sup>2</sup> Rivierduinen Eating Disorders Ursula, Leiden, The Netherlands

10 <sup>3</sup> Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North  
11 Carolina , USA

12 <sup>4</sup> Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North  
13 Carolina, USA

14

15 \* Corresponding author. Address: MEB, Karolinska Institutet, Nobels väg 12A, 171 77,  
16 Stockholm, Sweden

17 Email: [andreas.birgegard@ki.se](mailto:andreas.birgegard@ki.se)

18 Phone: +46-70-4843309

19

20 **Running title:** COVID-19 and eating disorders

21

22 **Acknowledgements:** Dr Bulik acknowledges support from the Swedish Research Council  
23 (Vetenskapsrådet, award: 538-2013-8864). The authors also thank Peter Lind for valuable  
24 support with IT.

25

26

27

## Abstract

**Objective:** To document the impact of the COVID-19 pandemic on the health and well-being of individuals with past and current eating disorders in Sweden.

**Method:** We re-contacted participants from two previous Swedish studies who had a known lifetime history of an eating disorder. Participants completed an online questionnaire about their health and functioning at baseline early in the pandemic (Wave 1;  $N=982$ ) and six months later (Wave 2);  $N=646$ ).

**Results:** Three important patterns emerged: 1) higher current eating disorder symptom levels were associated with greater anxiety, worry, and pandemic-related eating disorder symptom increase; 2) patterns were fairly stable across time, although a concerning number who reported being symptom-free at Wave 1 reported re-emergence of symptoms at Wave 2; and 3) only a minority of participants with current eating disorders were in treatment, and of those who were in treatment, many reported fewer treatment sessions than pre-pandemic and decreased quality of care.

**Conclusions:** The COVID-19 pandemic is posing serious health challenges for individuals with eating disorders, whether currently symptomatic or in remission. We encourage health service providers and patient advocates to be alert to the needs of individuals with eating disorders and to take active measures to ensure access to appropriate evidence-based care both during and following the pandemic.

**Keywords:** eating disorders, pandemic, COVID-19, social isolation, relapse

### Significant Outcomes and Limitations:

- Individuals with eating disorders symptoms or current active disorder report higher adverse impact of COVID-19 on their mental health
- Even individuals who were symptom-free early in the pandemic reported a resurgence of eating disorder symptoms
- A large proportion of symptomatic individuals were not in treatment for their eating disorder, services should be aware and access to evidence-based care should be ensured across Sweden
- Limitations included the use of a convenience sample with atypical diagnostic distribution, and a low initial response rate, possibly introducing bias and limiting generalisability.

63

64 **Data Availability Statement:** Fully anonymized data are available from the corresponding  
65 author upon request.

66

## Introduction

67 Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute  
68 respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic in March 2020  
69 by the World Health Organization. In response, countries across the globe implemented  
70 varying strict measures to limit the spread of the virus, balancing the impact of public health  
71 measures on social isolation, disruption of daily routines, and economic factors. Besides the  
72 direct and often prolonged impact of COVID-19 on physical and mental health,<sup>1,2</sup> pandemic-  
73 related restrictions have also adversely affected mental health in the general population,<sup>34</sup> and  
74 may worsen the symptoms in individuals with pre-existing psychiatric illnesses.<sup>56</sup> We surveyed  
75 a large sample of individuals with eating disorders (ED) in Sweden at two timepoints—Wave  
76 1 (baseline early in the pandemic) and Wave 2 (six months later)—to document the impact of  
77 the pandemic and public health measures taken to limit its transmission on individuals with  
78 EDs.

79

80 Several studies emerged in the literature early suggesting that the pandemic is adversely  
81 impacting individuals with ED. Reports from around the world suggest that exposure to  
82 triggering environments (e.g., having to spend more time in close quarters with family or  
83 roommates), lack of social support, and the absence of structure to daily life are particularly  
84 challenging for individuals with EDs.<sup>7,8</sup> Individuals surveyed report increases in ED symptoms,  
85 anxiety, and stress as a result of the pandemic.<sup>9,10</sup> In addition, disruption to clinical services in  
86 many countries has impeded access to treatment and initially, virtual care was rated as less  
87 satisfactory than typical face-to-face treatment.<sup>10,11</sup> Evidence of exacerbation of ED symptoms  
88 in individuals with an ED during the COVID-19 pandemic has been documented in studies  
89 from, for example, Spain<sup>12</sup>, Australia<sup>13</sup>, Germany<sup>14</sup>, the United States, and the Netherlands.<sup>10</sup>

90

91 Our primary aim was to characterize experiences of individuals with a current or past ED  
92 in Sweden during the COVID-19 pandemic using a longitudinal design with assessments at  
93 baseline (Wave 1) and after 6 months (Wave 2). Sweden-specific information is valuable as the  
94 country has had a unique response to COVID-19 public health management. We investigated  
95 changes in illness status over time, ED symptoms, anxiety, treatment availability, and COVID-  
96 19-related concerns. We also investigated baseline variables that were associated with  
97 deterioration or improvement of illness status over time. Our results provide valuable

98 information for patients and families, clinicians, and advocacy groups about needs of  
99 individuals with EDs in Sweden and have the potential to guide care strategies and resource  
100 planning during this and future pandemics.

101

102

103

## Material and Methods

104

### 105 Participants and procedure

106 We contacted all participants from two previous large-scale ED studies in Sweden: the  
107 Anorexia Nervosa Genetics Initiative (ANGI)<sup>15</sup> and the Binge Eating Genetics Initiative  
108 (BEGIN), who had given permission to be recontacted for future research. All participants  
109 had lifetime history of an ED (and many had current ED). Although all ED presentations were  
110 included, the majority of participants had anorexia nervosa (AN), given the nature of the  
111 parent ANGI study. Although all participants had verified diagnoses from the parent studies,  
112 for the purposes of this study, we used self-reported diagnosis and self-reported symptom  
113 status. We sent 3,774 emails on May 27<sup>th</sup> (170 emails were undeliverable) and when we froze  
114 first-wave data collection after six weeks, 982 individuals had responded (27%). The second  
115 wave, sent only to those who had completed the Wave 1 survey, was administered between  
116 December 22<sup>nd</sup> 2020 and February 2<sup>nd</sup> 2021, and 646 responded (66% of Wave 1). The study  
117 methodology was approved by the Swedish Ethical Review Authority (Dnr 2020-04136).

118

### 119 Survey

120 The survey (see Supplement 1) was modelled after a survey used in the United States and the  
121 Netherlands to study the impact of the pandemic on individuals with EDs (Termorshuizen et  
122 al.<sup>10</sup>) that queried physical and mental well-being related to COVID-19 in the previous two  
123 weeks. Participants provided data on age, sex, gender identity, diagnostic and treatment  
124 status, exposure to COVID-19, and current situational circumstances (e.g., quarantined,  
125 physical distancing). A Likert scale was used to measure level of concern about changes in  
126 ED symptoms, frequency of symptoms, and worry related to COVID-19. The 7-item version  
127 of the Generalised Anxiety Disorder Scale (GAD-7)<sup>16</sup> assessed anxiety, with Cronbach's  
128 alpha of .91 at Wave 1 and .92 at Wave 2. We applied the  $\geq 10$  cutoff<sup>16</sup> for possible  
129 diagnosable generalised anxiety disorder to categorize participants. Free-text items invited  
130 participants to share additional comments (qualitative analyses will be discussed elsewhere).

131

## 132 **Statistical analysis**

133 We defined three subgroups according to self-reported symptom status, with the question  
134 “Which of the following statements best describes your experience?” and response options “I  
135 have previously had an ED but am currently free of symptoms” (**NoSx**), “I have previously  
136 had an ED and still experience some symptoms” (**Sx**), and “I currently have an ED” (**ED**).  
137 Statistics for each wave are based on the symptom grouping reported at that timepoint,  
138 whereas longitudinal analyses (migration) are based on Wave 1 groupings. Distribution at  
139 both time points and migration across symptom groups over time are shown in Figure 1.

140

141 We examined changes in each symptom status group over time and baseline predictors of  
142 symptom deterioration or improvement using Welch’s *t*-tests (due to imbalanced design) and  
143 Cohen’s *d* effect sizes, by comparing those who changed group over time with baseline group  
144 peers who did not change. Three contrasts were possible based on statistical power: symptom  
145 deterioration (**NoSx**→**NoSx** vs. **NoSx**→**Sx**), and two comparisons marked by symptom  
146 improvement ( **Sx**→**Sx** vs. **Sx**→**NoSx** and **ED**→**ED** vs. **ED**→**Sx**). We selected baseline  
147 predictors that captured ED symptoms, anxiety level (GAD-7), and items that captured  
148 concerns about factors that might increase ED symptoms.

149

150 Attrition analyses compared Wave 2 responders with those who responded only at Wave 1 to  
151 investigate representativeness of the longitudinal subsample, on anxiety, worry about  
152 symptom increase, and ED symptoms-

153

154

155

## Results

156

### 157 **Sample characteristics and distribution of ED symptom groups**

158 The sample consisted of 98% biological females, and gender identity distribution was 97%  
159 female, 2% male, and 1% non-binary or other. Self-reported previous or current ED diagnosis  
160 distribution (participants could mark several response alternatives) was: anorexia nervosa  
161 64%; bulimia nervosa 37%; binge-eating disorder 24%; and other specified feeding and eating  
162 disorder 45%; with 12% other; and 1% responding “Don’t know/prefer not to answer”. Table  
163 1 shows descriptive statistics for COVID-19-related exposure and preventive measures at  
164 Wave 1 and Wave 2. No significant differences emerged between individuals who responded

165 to both waves of data collection and those who responded to Wave 1 only on any tested  
166 baseline variables.

167

168 {Insert Table 1 About Here}

169

170 Figure 1 shows the distribution of the symptom groups **NoSx**, **Sx**, and **ED** at each time point.  
171 Thirty-four percent had no ED symptoms, ~50% had lingering symptoms, and 16% reported a  
172 current active ED at each time point. Although the percentages at each timepoint were very  
173 similar, migration did occur. A full 23% of individuals transitioned from **NoSx** at Wave 1 to  
174 **Sx** at Wave 2 (i.e., deterioration); 15% of individuals with **Sx** at baseline reported **NoSx** at  
175 Wave 2 (i.e., improvement); and 21% of individuals with **ED** at Wave 1 reported **Sx** at Wave  
176 2 (i.e., improvement). The majority of individuals, however, remained in the same symptom  
177 category across time.

178

179 {Insert Figure 1 About Here}

180

181

## 182 **Anxiety and ED symptom variables by symptom status group**

183 Table 2 reveals that individuals in all three symptoms groups were more likely to say that  
184 their anxiety had increased since the end of 2019 at Wave 2 than at Wave 1. In most cases  
185 across symptom groups and at both waves, participants were more likely to attribute their  
186 increases in anxiety to COVID-19 (data not shown).

187

188 {Insert Table 2 About Here}

189

190 GAD-7 was strongly associated with symptom group, and patterns were similar across waves.  
191 At both Wave 1 and Wave 2, 23% of the **NoSx** group, ~50% of the **Sx** group, and 79% (Wave  
192 1) and 76% (Wave 2) of the **ED** group scored above the cut-off for GAD-7.

193

194 {Insert Figure 2 About Here}

195

196

197

198 Table 3 shows that concern about ED symptom increase due to the pandemic<sup>1</sup> was strongly  
199 related to symptom status group. Participants in **ED** were more concerned about increased  
200 symptoms due to lack of structure and social support, and being exposed to triggering  
201 environments, than **Sx**, who in turn were more concerned than **NoSx**. Patterns were similar  
202 across waves.

203

204 Table 3 further shows that more participants reported being worried about others being  
205 infected by COVID-19 than themselves, and increased ED symptom level status was  
206 associated with higher worry. Further, participants were much more worried about their  
207 mental health being affected than physical health, and there was a clear pattern of higher ED  
208 symptoms being associated with higher levels of concern.

209

210 {Insert Table 3 About Here}

211

212 A similar pattern emerged with ED symptoms, with increasing symptoms of binge eating,  
213 restrictive eating, and compensatory behaviours across **NoSx**, **Sx**, and **ED** groups. Concern  
214 about not being able to exercise was similar in both **ED** and **Sx**. Patterns were similar across  
215 waves.

216

### 217 **Treatment**

218 Table 4 presents treatment-related results. Notably, the majority of individuals with active  
219 EDs reported not being in current treatment. Most notably, a majority had no current ED  
220 treatment, 40% had had fewer sessions in the last two weeks, and a substantial proportion  
221 experienced their treatment quality as worse or much worse than before the pandemic. On the  
222 other hand, fairly many still had face-to-face sessions and a majority experienced their  
223 treatment as good or better than before the pandemic.

224

### 225 **Migration between symptom status groups**

226 We conducted two analyses exploring Wave 1 predictors of a change in symptom status  
227 between Wave 1 and Wave 2 (Table 5). Two analyses investigated factors associated with  
228 deterioration and two related to improvement.

---

<sup>1</sup> Some response options in this item (“concern”, see Supplement 1) are not shown since scores were very low as the response options are relatively irrelevant for Swedish conditions; these related to concern about not being able to afford food or treatment, which is not an issue in Sweden at this point.



229 Those individuals who transitioned from **NoSx** to **Sx** had significantly higher Wave 1 mean  
230 GAD-7 scores, greater concern about being in a triggering environment, and higher worry  
231 about not being able to exercise, with medium effect sizes. They also had significantly higher  
232 concern about lack of structure and social support, but with small effect sizes.  
233 Individuals who transitioned from **Sx** at Wave 1 to **No Sx** at Wave 2 had lower scores on  
234 concerns about lack of structure, social support, and being in a triggering environment and  
235 lower scores on compensatory behaviours, with small to medium effects. Individuals who  
236 moved from **ED** at Wave 1 to **Sx** at Wave 2 had lower baseline GAD-7 scores.

237

238 {Insert Tables 4 and 5 About Here}

239

240

## Discussion

241

242 We characterized experiences of people with a current or past ED early in the COVID-19  
243 pandemic and six months later. Using a survey coordinated with studies in the USA and the  
244 Netherlands, we identified three important patterns. First, the higher the current ED symptom  
245 level of the participant, the more anxiety, worry, and ED symptom increase was reported.  
246 Second, results were fairly stable across time, with some exceptions. Third, quite  
247 concerningly, only a minority of participants with current ED were in treatment, and of those  
248 who were in treatment many reported fewer treatment sessions than usual and decreased  
249 quality of care.

250

251 The overall impression is that among people with experience of an ED, those with  
252 lingering symptoms or current active disorder are particularly vulnerable to the disruptions  
253 and anxiety caused by the COVID-19 pandemic and the societal restrictions that have  
254 necessarily been put in place. GAD-7 results suggested that a full three-quarters of individuals  
255 with active EDs were likely to also have generalised anxiety disorder. In the absence of pre-  
256 pandemic data, we are unable to determine whether this is higher than would be expected, but  
257 regardless it reflects the importance of attending to anxiety in the treatment of individuals  
258 with EDs during the pandemic. Although we found relatively few relapses into ED, a  
259 concerning number who initially reported being symptom-free reported re-emergence of  
260 symptoms as the pandemic progressed.

261

262           Regarding predictors of deteriorating symptoms, baseline anxiety, weaker social support  
263 and structure, and fears about not being able to exercise were all associated with worsening  
264 ED symptoms. Symptom improvement showed to some extent the opposite pattern, as it was  
265 associated with lower anxiety and higher ratings on social support and structure. These results  
266 may be especially informative for treatment planning and safeguarding continued recovery,  
267 since they underscore the importance of ensuring that individuals with current or past EDs  
268 have skills to address anxiety and strategies to forge social connectedness as well as support  
269 and adequate structure to their daily lives.

270

271           Intriguingly, our results closely mirror results reported in the US and the Netherlands,<sup>10</sup>  
272 suggesting that despite considerable differences in the public health measures used across the  
273 three countries to contain transmission of COVID-19, the impact on individuals with EDs was  
274 comparable. Indeed, EDs thrive in social isolation with patients reporting feeling alone with  
275 their ED thoughts and isolated in terms of monitoring their weight and eating. Since  
276 developing regular and adequate eating is central to ED recovery and maintenance of  
277 treatment gains, the absence of a predictable daily structure removes a central component of  
278 ED care.

279

280           Our results have direct clinical implications for clinicians working with ED patients  
281 during the pandemic as well as for advocacy organizations who provide additional support.  
282 Even if patients have been transitioned to virtual care, it is important to ensure that they have  
283 adequate social support via families, peers, advocacy organizations, or even online forums to  
284 maintain accountability and motivation for recovery. It is also essential to assess directly  
285 individuals' living arrangements. Given limitations on socializing and recommendations for  
286 physical distancing during the pandemic, individuals may find themselves with less freedom  
287 and flexibility to extricate themselves from unhelpful or even toxic environments. Remaining  
288 vigilant for triggering situations and providing practical assistance with managing them is of  
289 critical import. Finally, assisting patients with developing and maintaining structure to their  
290 daily lives, especially when working from home, can aid recovery. Providing support, social  
291 connectedness, and daily structure are three clinical targets that appear to be critical to ED  
292 patients during the pandemic.

293

294           Although our study provides important knowledge about how individuals with ED are  
295 coping with the pandemic, it has several limitations. First, given our intention to field a survey

296 soon after COVID-19 was declared a global pandemic, we rapidly translated and adapted a  
297 survey used in the US and the Netherlands. This precluded typical steps to ensure sound  
298 psychometric properties. Second, we relied on a convenience sample (i.e., individuals who  
299 had participated in previous studies who agreed to be contacted for future research), which  
300 did not reflect the distribution of diagnoses to be expected from a community sample and may  
301 have biased results. Third, we relied on self-report diagnosis and symptom reports to  
302 characterize patients. Although all participants had formal diagnoses in the past, the use of  
303 self-reports to establish current status remains a limitation. Fourth, our response rate to the  
304 initial survey was low (27%) and we experienced attrition between the waves, again  
305 potentially introducing bias and limiting generalisability. Finally, we were underpowered for  
306 some analyses; group sizes were low for analysing transitions between symptom levels across  
307 time.

308

309 Nevertheless, we were able to capture fairly early on in the pandemic how individuals  
310 with ED were being affected. As anticipated, COVID-19 has been particularly challenging for  
311 those with existing active mental disorders, and even those who are currently symptom-free  
312 are challenged to remain healthy. We encourage clinicians and advocacy organizations to  
313 avail themselves of these results to aid in developing resources for patients, families, and  
314 clinicians for dealing with ED during the pandemic. Given the frequency with which  
315 individuals with active EDs reported not being in treatment and the concerning number who  
316 initially reported being symptom-free who subsequently reported re-emergence of symptoms  
317 six months later, we encourage health service providers and patient advocates to be alert to  
318 the needs of ED patients and to take active measures to ensure access to appropriate evidence-  
319 based care for all EDs across Sweden during the pandemic and subsequently when there may  
320 be a serious backlog of individuals requiring care.

321

322

## References

- 323 1. Butler M, Pollak TA, Rooney AG, Michael BD, Nicholson TR. Neuropsychiatric  
324 complications of covid-19. *The BMJ*. 2020;371. doi:10.1136/bmj.m3871
- 325 2. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19.  
326 *JAMA - Journal of the American Medical Association*. 2020;324(6).  
327 doi:10.1001/jama.2020.12603
- 328 3. The Lancet Psychiatry. Mental health and COVID-19: change the conversation. *The*  
329 *Lancet Psychiatry*. Published online 2020. doi:10.1016/S2215-0366(20)30194-2
- 330 4. Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in  
331 the general population: A systematic review. *Journal of Affective Disorders*. 2020;277.  
332 doi:10.1016/j.jad.2020.08.001
- 333 5. Gobbi S, Plomecka MB, Ashraf Z, et al. Worsening of Preexisting Psychiatric  
334 Conditions During the COVID-19 Pandemic. *Frontiers in Psychiatry*. 2020;11.  
335 doi:10.3389/fpsy.2020.581426
- 336 6. Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric  
337 symptoms during COVID-19 pandemic and lockdown? A case-control study with  
338 service and research implications for immunopsychiatry. *Brain, Behavior, and*  
339 *Immunity*. 2020;87. doi:10.1016/j.bbi.2020.04.069
- 340 7. Geller J, Iyar M, Srikameswaran S, Zelichowska J, Dunn EC. Social support  
341 satisfaction in adults with eating disorders: Does stance matter? *International Journal*  
342 *of Eating Disorders*. 2017;50(7). doi:10.1002/eat.22695
- 343 8. Lindstedt K, Neander K, Kjellin L, Gustafsson SA. Being me and being us -  
344 Adolescents' experiences of treatment for eating disorders. *Journal of Eating*  
345 *Disorders*. 2015;3(1). doi:10.1186/s40337-015-0051-5
- 346 9. Chan CY, Chiu CY. Disordered eating behaviors and psychological health during the  
347 COVID-19 pandemic. *Psychology, Health & Medicine*. Published online 2021.  
348 doi:10.1080/13548506.2021.1883687
- 349 10. Termorshuizen JD, Watson HJ, Thornton LM, et al. Early impact of COVID-19 on  
350 individuals with self-reported eating disorders: A survey of ~1,000 individuals in the  
351 United States and the Netherlands. *International Journal of Eating Disorders*.  
352 2020;53(11). doi:10.1002/eat.23353
- 353 11. Weissman RS, Bauer S, Thomas JJ. Access to evidence-based care for eating  
354 disorders during the COVID-19 crisis. *International Journal of Eating Disorders*.  
355 2020;53(5). doi:10.1002/eat.23279

- 356 12. Fernández-Aranda F, Casas M, Claes L, et al. COVID-19 and implications for eating  
357 disorders. *European Eating Disorders Review*. Published online 2020.  
358 doi:10.1002/erv.2738
- 359 13. Phillipou A, Meyer D, Neill E, et al. Eating and exercise behaviors in eating disorders  
360 and the general population during the COVID-19 pandemic in Australia: Initial results  
361 from the COLLATE project. *International Journal of Eating Disorders*. 2020;53(7).  
362 doi:10.1002/eat.23317
- 363 14. Schlegl S, Maier J, Meule A, Voderholzer U. Eating disorders in times of the  
364 COVID-19 pandemic—Results from an online survey of patients with anorexia  
365 nervosa. *International Journal of Eating Disorders*. 2020;53(11).  
366 doi:10.1002/eat.23374
- 367 15. Thornton LM, Munn-Chernoff MA, Baker JH, et al. The Anorexia Nervosa Genetics  
368 Initiative (ANGI): Overview and methods. *Contemporary Clinical Trials*. 2018;74.  
369 doi:10.1016/j.cct.2018.09.015
- 370 16. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing  
371 generalized anxiety disorder: The GAD-7. *Archives of Internal Medicine*.  
372 2006;166(10). doi:10.1001/archinte.166.10.1092

Table 1.

*COVID-19 exposure and preventive measures; % “Yes” responses (See Supplement for full questionnaire)*

<b>Item</b>	<b>Wave 1 n (%)</b>	<b>Wave 2 n (%)</b>
Practicing social distancing	749 (77%)	556 (87%)
Forced isolation	10 (1%)	3 (1%)
Work/study from home	457 (47%)	341 (53%)
Ordered home stay	51 (5%)	37 (6%)
Tested positive for COVID-19	17 (2%)	56 (9%)
Clinical COVID-19 diagnosis	6 (1%)	4 (1%)
Have not had COVID-19	618 (63%)	443 (69%)
Maybe had COVID-19 but not sure	336 (34%)	139 (22%)

Table 2.

*Changes in self-reported anxiety by symptom group.*

Item	Group	“No change”		“Increased”		“Decreased”	
		Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2
<i>Anxiety level changed since the end of 2019?</i>	<b>NoSx</b>	48%	43%	34%	41%	17%	17%
	<b>Sx</b>	35%	29%	51%	54%	14%	17%
	<b>ED</b>	33%	20%	58%	67%	10%	14%

*Note:* NoSx=No ED symptoms; Sx=Some remaining symptoms; ED=Current eating disorder

Table 3.

*Worry about impact of COVID-19 by symptom group and measurement wave for items related to concern about factors leading to increased ED symptoms, ED symptoms themselves, and worry about the impact of COVID-19 on others and own health. See Supplement for items.*

Variable	Response options shown	Symptom group	Wave 1	Wave 2
Worry that ED symptoms increase due to lack of structure	Per cent responding “Fairly worried” to “Very worried”	NoSx	10%	7%
		Sx	33%	31%
		ED	56%	61%
Worry that ED symptoms increase due to lack of social support		NoSx	3%	4%
		Sx	20%	19%
		ED	51%	48%
Worry that ED symptoms increase due to being in a triggering environment		NoSx	9%	6%
		Sx	32%	32%
		ED	56%	53%
Binge eating bunkered food	Per cent responding “Often” to “Daily or more”	NoSx	1%	1%
		Sx	8%	7%
		ED	24%	23%
Restricted food intake due to COVID-19-related factors		NoSx	5%	2%
		Sx	14%	11%
		ED	27%	24%
Compensated for food intake food intake due to COVID-19-related factors		NoSx	1%	1%
		Sx	9%	8%
		ED	26%	28%
Worried about not being able to exercise		NoSx	17%	18%
		Sx	36%	37%
		ED	39%	46%
Worry about self being infected	Per cent responding “Fairly worried” to “Very worried”	NoSx	23%	39%
		Sx	28%	38%
		ED	32%	40%
Worry about others being infected		NoSx	79%	79%
		Sx	78%	84%
		ED	80%	86%
Worry about physical health being affected		NoSx	28%	39%
		Sx	37%	50%
		ED	45%	54%
Worry about mental health being affected		NoSx	42%	50%
		Sx	59%	65%
		ED	65%	73%

*Note:* NoSx=No ED symptoms; Sx=Some remaining symptoms; ED=Current eating disorder

Table 4.

Experiences of treatment.

Item	“F2F sessions”		“Transitioned to virtual”		“No sessions”		“Not in treatment”	
	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2
<i>Presence and format of treatment</i>	27%	28%	10%	9%	7%	13%	58%	51%
<i>Change in session frequency</i>	“Fewer sessions”		“As many sessions”		“More sessions”			
	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2		
	40%	41%	53%	54%	7%	5%		
<i>Change in ED treatment quality</i>	“Better”		“As good”		“A little worse”		“Much worse”	
	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2	Wave 1	Wave 2
	4%	5%	56%	49%	29%	30%	11%	16%

Note: F2F=Face to face; ED=eating disorder. Responses regarding treatment were reported for the ED group only (Wave 1 n=156, Wave 2 n=102). Responses regarding change in session frequency and treatment quality were asked only to those who responded to have had face-to-face or virtual sessions in the past two weeks (Wave 1 n=55, Wave 2 n=37).



Table 5.

Descriptive statistics, Welch's *t*-tests and Cohen's *d* effect sizes of the three migration analyses using baseline variables; Stable NoSx vs. NoSx → Sx (*n*=168 vs. 51), Stable Sx vs. Sx → NoSx (*n*=252 vs. 45), and Stable ED vs. ED → Sx (*n*=84 vs. 23). See Supplementary 1 for item wording.

Compared groups	GAD-7	Worry about mental health being affected	Concern about lack of structure	Concern about lack of social support	Concern about triggering environment	Binge eating	Restrictive eating	Compensatory symptoms (e.g. vomiting)	Worry about no exercise
	<i>M</i> ( <i>SD</i> )	<i>M</i> ( <i>SD</i> )	<i>M</i> ( <i>SD</i> )	<i>M</i> ( <i>SD</i> )	<i>M</i> ( <i>SD</i> )	<i>M</i> ( <i>SD</i> )	<i>M</i> ( <i>SD</i> )	<i>M</i> ( <i>SD</i> )	<i>M</i> ( <i>SD</i> )
Stable NoSx	6.0 (4.24)	1.7 (.78)	1.4 (.68)	1.2 (.42)	1.3 (.58)	1.1 (.27)	1.2 (.52)	1.1 (.30)	1.6 (.83)
vs. NoSx → Sx	***, ††	*	*, †	*, †	** ; ††				** ; ††
	9.2 (5.60)	1.8 (.67)	1.7 (.88)	1.4 (.64)	1.8 (1.02)	1.2 (.43)	1.3 (.68)	1.1 (.35)	2.1 (1.04)
Stable Sx	10.2 (5.43)	1.8 (.68)	2.2 (.97)	1.8 (.96)	2.1 (1.02)	1.4 (.64)	1.5 (.76)	1.4 (.65)	2.1 (1.09)
vs. Sx → NoSx			** ; †	** ; †	* ; †			* ; †	
	9.4 (5.62)	1.8 (.64)	1.8 (.84)	1.4 (.69)	1.7 (.92)	1.3 (.64)	1.5 (.76)	1.2 (.46)	2.0 (1.02)
Stable ED	14.5 (4.95)	1.8 (.58)	2.7 (1.13)	2.6 (1.13)	2.6 (1.07)	1.6 (.94)	1.7 (.94)	1.7 (.96)	2.1 (1.11)
vs. ED → Sx	*								
	11.6 (4.98)	1.6 (.66)	2.6 (1.23)	2.4 (1.11)	3.0 (1.07)	2.0 (1.04)	1.5 (.73)	1.7 (.94)	2.3 (1.02)

\* *p*<.05; \*\* *p*<.01; \*\*\* *p*<.001. † *d* ≥ .20 (small effect); †† *d* ≥ .50 (medium effect).

Note: NoSx=No ED symptoms; Sx=Some remaining symptoms; ED=Current eating disorder; GAD-7=Generalised anxiety disorder 7-item scale; ICB=name of the ED symptom items.

## Figure Legends.

**Figure 1.** Distribution ( $n$ , %) of participants into self-reported symptom-level groups at each measurement wave, where **NoSx**=previous ED but no current symptoms, **Sx**=previous ED and remaining symptoms, and **ED**=current ED. Circle sizes approximate group size, and migration between groups (arrows) is displayed with percentage of starting group moving to another.

**Figure 2.** Proportion of individuals scoring above/below the GAD-7 cut-off ( $\geq 10$ ) at each time wave, separated by ED status group.




Figure 1.




Figure 2.